Early Intervention for Psoriasis With Guselkumab Tied to Complete Response
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, June 14, 2023 -- Guselkumab is consistently effective across subpopulations for the treatment of moderate-to-severe plaque psoriasis, according to a study published June 1 in the Journal of the European Academy of Dermatology & Venereology.
Knut Schäkel, M.D., from Heidelberg University Hospital in Germany, and colleagues evaluated the impact of early disease intervention on clinical responses following 28 weeks of guselkumab treatment in patients with moderate-to-severe plaque psoriasis. The analysis included 880 patients with a short disease duration (SDD; no more than two years; 40.6 percent) or a long disease duration (LDD; more than two years) receiving guselkumab 100 mg at weeks 0, 4, 12, 20, and 28.
The researchers found that more patients with SDD achieved absolute Psoriasis Area and Severity Index (PASI) scores of 0 at week 28 (51.8 versus 39.4 percent among LDD patients) and were super responders with complete skin clearance from weeks 20 to 28 (43.7 versus 28.1 percent). The median time to PASI of 0 was shorter among SDD patients than LDD patients (141 versus 200 days). Disease duration and prior biologic use were not independently associated with super response status. Across all patient groups, guselkumab was associated with a rapid decrease in markers of systemic inflammation at week 4.
"The proportion of [super responders] was higher in SDD than LDD patients, indicating early treatment intervention may improve clinical outcomes," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Janssen-Cilag, which manufactures guselkumab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Coexistence of Psoriatic Arthritis, Atopic Dermatitis May Offer Treatment Insights
MONDAY, May 13, 2024 -- Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both conditions may mean special attention should be given to...
Tobacco Smoking Reduces the Odds of Psoriasis Improvement
WEDNESDAY, April 24, 2024 -- Tobacco smoking is negatively associated with resolution of psoriasis symptoms, according to a study published in the April issue of Tobacco Induced...
AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis
FRIDAY, March 15, 2024 -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.